{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:00:32Z","timestamp":1790290832294,"version":"4.1.0"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This retrospective single-center study sought to evaluate the efficacy and safety of predictive tumor-absorbed ablative doses of Yttrium-90 resin microsphere selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC).<\/jats:p>\n                  <jats:p>We conducted a retrospective single-center study of patients with HCC treated at a tertiary referral center, who underwent Y-90 resin SIRT with ablative intent (defined as predictive tumor absorbed dose (TAD) of at least 190 Gy via planning single-photon emission computed tomography-CT dosimetry) between January 2016 and December 2023, evaluating radiological response and survival outcomes.<\/jats:p>\n                  <jats:p>Among 68 patients, median TAD was 262.24 Gy (interquartile range 209.13 Gy-336.26 Gy). Median follow-up was 1,231 days (approximately 40.4 months). At 6 and 12 months post-treatment, objective response (OR) and disease control rates (DCR) in the target tumors were 87.5% and 96.9%, and 73.6% and 86.8%, respectively, assessed with modified Response Evaluation Criteria in Solid Tumors (mRECIST) on imaging.<\/jats:p>\n                  <jats:p>Median target tumor time to progression (TTP) was not reached (95% CI: 785 days \u2013 not reached); portal venous invasion was an independent predictor for shorter TTP (HR 7.34, 95% CI 1.57\u201334.4, p\u2009=\u20090.011). Median progression-free survival (PFS) was 453.0\u2009days (95% CI, 287\u2013577). Barcelona Clinic Liver Cancer stages B\/C (HR 2.87, 95% CI 1.49\u20135.53, p\u2009=\u20090.0016) and the absence of subsequent curative treatment (HR 2.13, 95% CI 1.10\u20134.12, p\u2009=\u20090.026) predicted for poorer PFS.<\/jats:p>\n                  <jats:p>Median overall survival (OS) was 1,412 days (95% CI 596\u2013NR). Absence of subsequent curative treatment predicted for poorer OS (HR 5.23, 95% CI 1.66\u201316.48, p\u2009=\u20090.005). Median OS for the 190 to 300 Gy group was 699 days (95% CI 531\u20132,244 days), and 1,446 days (95% CI 796 days \u2013 NR) for the TAD&gt; 300 Gy group, though observed differences in OS between the groups were not statistically significant. Two patients had possible radiation-induced liver disease, two had post-embolization syndrome, and two had radiation-induced peptic ulcer disease. These six patients were primarily responsible for the grade 2 and 3 adverse events recorded.<\/jats:p>\n                  <jats:p>Y-90 resin SIRT with predictive TAD of at least 190 Gy in HCC can achieve favorable 1-year target tumor disease control and a median OS of 46.4 months. Absence of subsequent curative treatment independently predicted inferior progression-free and overall survival. Among plausible reasons for the absence of a clear dose\u2013response relationship, TAD substantially higher than 190 Gy may be required for consistent ablative efficacy.<\/jats:p>","DOI":"10.1055\/s-0046-1825760","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:12:11Z","timestamp":1784157131000},"page":"197-207","source":"Crossref","is-referenced-by-count":0,"title":["Real World Outcomes of Prescribed Ablative Dose Yttrium-90 Resin Selective Internal Radiation Therapy of Hepatocellular Carcinoma"],"prefix":"10.1055","volume":"25","author":[{"given":"Si Xuan","family":"Koo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You Kai","family":"Poh","sequence":"additional","affiliation":[{"name":"Division of Supportive and Palliative Care, National Cancer Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9230-1289","authenticated-orcid":false,"given":"Nathaniel Sheng Hua","family":"Too","sequence":"additional","affiliation":[{"name":"Duke-National University of Singapore Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Ming","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond Shi Wei","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Xian Yang","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-9857","authenticated-orcid":false,"given":"Winnie Wing Chuen","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Siu Hoong","family":"Loke","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Kian Ti","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.116.184713","article-title":"Resin versus glass microspheres for Y90-transarterial radioembolization: comparing survival in unresectable hepatocellular carcinoma using pretreatment partition model dosimetry","volume":"58","author":"A Van Der Gucht","year":"2017","journal-title":"J Nucl Med"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"R Salem","year":"2021","journal-title":"Hepatology"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"J A Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/hep.27057","article-title":"Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy","volume":"60","author":"M Vouch\u00e9","year":"2014","journal-title":"Hepatology"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","article-title":"Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants","volume":"48","author":"A Gabr","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jvir.2020.12.019","article-title":"Pathologic response of hepatocellular carcinoma treated with yttrium-90 glass microsphere radiation segmentectomy prior to liver transplantation: a validation study","volume":"32","author":"B Toskich","year":"2021","journal-title":"J Vasc Interv Radiol"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"R Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"E Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"02","key":"ref10","first-page":"158","article-title":"The impact of radiation dose and tumour burden on outcomes in hepatocellular carcinoma: 11-year experience in a 413-patient cohort treated with yttrium-90 resin microsphere radioembolisation","volume":"14","author":"K Chen","year":"2024","journal-title":"Liver Cancer"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","volume":"48","author":"H Levillain","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"e231386","DOI":"10.1148\/radiol.231386","article-title":"Efficacy and safety of radiation segmentectomy with Y-90 resin microspheres for hepatocellular carcinoma","volume":"311","author":"A Sarwar","year":"2024","journal-title":"Radiology"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jvir.2023.02.030","article-title":"Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: a comparative study of the effectiveness, safety, and dosimetry of glass-based versus resin-based microspheres","volume":"34","author":"A Villalobos","year":"2023","journal-title":"J Vasc Interv Radiol"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00259-023-06111-9","article-title":"Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study","volume":"50","author":"N Kokabi","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/RLU.0000000000005198","article-title":"Resin-based 90Y tumor dose as a predictor of duration of response and survival in patients with surgically unresectable hepatocellular carcinoma: a prospective single-arm study","volume":"49","author":"N Kokabi","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-0044-1779715","article-title":"Yttrium-90 radioembolization dosimetry: dose considerations, optimization, and tips","volume":"41","author":"A Villalobos","year":"2024","journal-title":"Semin Intervent Radiol"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00259-025-07471-0","article-title":"Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheres","volume":"53","author":"A Sarwar","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.31318","article-title":"Liver transplantation following yttrium-90 radioembolization: 15-year experience in a 207-patient cohort","volume":"73","author":"A Gabr","year":"2021","journal-title":"Hepatology"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jvir.2018.06.027","article-title":"Outcomes of surgical resection after yttrium-90 radioembolization for hepatocellular carcinoma","volume":"29","author":"A Gabr","year":"2018","journal-title":"J Vasc Interv Radiol"},{"issue":"02","key":"ref20","first-page":"100633","article-title":"Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study","volume":"5","author":"F Kolligs","year":"2022","journal-title":"JHEP Rep Innov Hepatol"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0046-1825760.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:30:40Z","timestamp":1790289040000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0046-1825760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":19,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,9,24]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0046-1825760","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}